Back to all companies
Sign in
Back to all companies
Engage Bio logo

Engage Bio

Winter 2022Acquired

Potent, durable, and redosable non-viral genetic medicines

Save
Engage Bio logo

Engage Bio

Winter 2022Acquired

Potent, durable, and redosable non-viral genetic medicines

Save
Company details

Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.

In 2026 Engage was acquired by Eli Lilly.

Location
San Francisco, CA, USA
Founded
Unknown
Category
Synthetic Biology
YC Directory Pageengagebio.com
Founder
  • WO
    Will Olsen
    Founder
    LinkedIn

Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.

In 2026 Engage was acquired by Eli Lilly.

Location
San Francisco, CA, USA
Founded
Unknown
Category
Synthetic Biology
YC Directory Pageengagebio.com
Founder
  • WO
    Will Olsen
    Founder
    LinkedIn
Pro

Upgrade to Pro, then request the Engage Bio teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate Engage Bio. The full teardown, rebuild plan, and technical specs unlock when it lands.

  • Use Pro to request the first Engage Bio teardown and keep the finished report in your account.
  • Read every completed teardown and rebuild plan already in the database.
  • Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans
Full teardown library
Specs for every company
5 fresh requests / month
CLI for agent imports
Startups.RIP — Dead startups, alive ideas
PricingContactPrivacyGot feedback? DM @oscrhong